Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

NCT03029858 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT03029858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03029858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2017
Completion date
September 30, 2020
Enrollment
155 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer, polygonal type